Shamburg News · 8-K filed Nov 9, 2026, 7:49 AM EST
CorMedix to Acquire Substantially All Assets of Heron Therapeutics for $145 Million Cash Plus Stock
CRMD · CorMedix Inc.
- Material agreement
- Acquisition
- Financing
- Reg FD disclosure
- Materiality: high
On November 8, 2026, CorMedix entered into an Asset Purchase Agreement to acquire substantially all assets of Heron Therapeutics for $145.0 million in cash subject to adjustments, 14,583,333 shares of CorMedix common stock, a 5.0% royalty on certain net sales above $25.0 million in 2027 through 2029, and earn-out payments of up to $55.0 million tied to 2028 ZYNRELEF net sales. The company also entered a senior secured term loan agreement with Pharmakon-managed funds providing up to $150.0 million, with a $75.0 million Tranche A to fund the transaction. Closing is subject to Heron stockholder approval, HSR clearance, and other customary conditions, and Heron agreed to pay a $4.0 million termination fee in specified circumstances.
Source: SEC EDGAR, Form 8-K, Items 1.01, 2.03, 3.02, 7.01, 9.01, accession 0001213900-26-117213.
Written from the filing by Shamburg Markets. Figures are as reported by the company.